Business
MDK Oncology Antibodies Demonstrate In-Vivo Safety
MDK Oncology Antibodies Demonstrate In-Vivo Safety.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 24 January 2023\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n MDK Oncology Antibodies Demonstrate In-Vivo Safety\n \n \n Development milestone achieved\n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\n the Main Market listed biotech company focused on\n developing first in class medicines in the high growth, high value oncology market\n is pleased to announce the ROQ-A1 and ROQ-A2 Midkine (\"MDK\") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups.\n \n \n \n \n \n As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney).\n \n \n \n \n \n ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro.\n \n \n \n \n \n \n \n The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget.\n \n \n \...